What insurance policy changes affect code T45.AX5S?

There are 2 tracked policy changes affecting code T45.AX5S, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code T45.AX5S?

Payers that have issued tracked updates for code T45.AX5S include: Aetna.

How do I get notified when code T45.AX5S policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code T45.AX5S. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code T45.AX5S?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

T45.AX5S Insurance Policy Changes

ICD-10 T45.AX5S is officially defined as "Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela." code T45.AX5S is referenced in 2 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code T45.AX5S is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Only a small number of policies match this filter. Check back as coverage expands.

Watch T45.AX5S

Get one email when a payer policy names T45.AX5S, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

T45.AX5S Insurance Policy Changes

Siltuximab (Sylvant) (CPB 0884, reviewed 2026-06-03)

Etanercept (CPB 0315, reviewed 2026-07-08)